Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
暂无分享,去创建一个
A. Zelenetz | D. Scheinberg | P. Maslak | K. Panageas | D. Golde | M. Heaney | R. Brentjens | J. Jurcic | A. Noy | M. Weiss | N. Lamanna | A. Gencarelli